Universitat de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2018

  1. Arrhythmias in congenital heart disease: A position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE

    Europace, Vol. 20, Núm. 11, pp. 1719-1720

2017

  1. Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE

    European Journal of Preventive Cardiology, Vol. 24, Núm. 1, pp. 41-69

  2. Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE

    Europace, Vol. 19, Núm. 1, pp. 139-163

2016

  1. Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases

    Cardiology and Therapy, Vol. 5, Núm. 1, pp. 75-82

  2. Erratum to: Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases (Cardiology and Therapy, (2016), 5, 1, (75-82), 10.1007/s40119-016-0059-1)

    Cardiology and Therapy

2014

  1. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: A multicentre, randomized, controlled trial (SARA study)

    European Heart Journal, Vol. 35, Núm. 8, pp. 501-507

2012

  1. Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response?

    European Journal of Heart Failure, Vol. 14, Núm. 6, pp. 635-641

2005

  1. Predictors of lack of response to resynchronization therapy

    American Journal of Cardiology, Vol. 95, Núm. 12, pp. 1436-1440